Evidence map›Paper›PMID 42315254›Full record

ReviewJournal for immunotherapy of cancer2026

Mapping the TCR landscape: computational tools empowering translational immunology and therapy design.

Pâmella Borges, Martiela Vaz de Freitas, Jinkyung Yoo, Finn Beruldsen, Jaila Lewis, Francisca Joseli Freitas de Sousa, Sae Hee Choi, Duy Bao Nguyen, Geancarlo Zanatta, Jeong Hoon Jang and 6 more

Abstract readReview
In one paragraph

Review in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pâmella BorgesBiology and Biochemistry, University of Houston, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-2250-7112
Martiela Vaz de FreitasBiology and Biochemistry, University of Houston, Houston, Texas, USA.
Jinkyung YooMathematics, University of Houston, Houston, Texas, USA.
Finn BeruldsenBiology and Biochemistry, University of Houston, Houston, Texas, USA.
Jaila LewisBiology and Biochemistry, University of Houston, Houston, Texas, USA.
Francisca Joseli Freitas de SousaBiochemistry and Molecular Biology, Universidade Federal do Ceará, Fortaleza, Brazil.
Sae Hee ChoiBiology and Biochemistry, University of Houston, Houston, Texas, USA.
Duy Bao NguyenComputer Science, University of Houston, Houston, Texas, USA.ORCID http://orcid.org/0009-0001-7336-4644
Geancarlo ZanattaPostgraduate program in Biochemistry, Universidade Federal do Ceará, Fortaleza, Brazil.
Jeong Hoon JangBiostatistics and Data Science, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
Eduardo DonadiMedicine, Universidade de São Paulo, São Paulo, Brazil.
Houda AlachkarClinical Pharmacy, University of Southern California, Los Angeles, California, USA.ORCID http://orcid.org/0000-0001-5567-5521
Steven P WolfDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.ORCID http://orcid.org/0009-0008-2723-695X
Maurício Menegatti RigoDepartment of Molecular Biology and Biotechnology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Hyeongseon JeonMathematics, University of Houston, Houston, Texas, USA.
Dinler Amaral AntunesBiology and Biochemistry, University of Houston, Houston, Texas, USA dinler@uh.edu.ORCID http://orcid.org/0000-0001-7947-6455

Funding

Structure-guided cancer immunotherapy design with HLA-Arena and CrossDomeR21CA289333 · NCI · UNIVERSITY OF HOUSTON · PI ANTUNES, DINLER · 2024 to 2024
$415k
NCI NIH HHS R21 CA289333
6 · The paper itself

Abstract

T cell receptors (TCRs) are central to adaptive immunity, yet their vast sequence and structural diversity present a significant challenge to fully understand immune responses. The application of high-throughput sequencing technologies, including bulk and single-cell approaches, generates vast datasets of TCR repertoire information, requiring advanced computational tools for meaningful analysis. Here, we provide a comprehensive overview of the state-of-the-art in silico tools developed to enable diverse TCR repertoire analyses. We categorize over 40 computational tools into six primary analytical stages creating a workflow for TCR analysis in the context of cancer immunotherapy: (1) data acquisition, including differences between TCR sequencing technologies and databases; (2) TCR reconstruction and inference, which focuses on accurately extracting from raw sequencing data the V(D)J gene usage, including complementarity-determining region sequences, and the α/β pairing; (3) TCR clustering, which groups receptors based on similarity, helping characterize repertoire shifts, therapy responses and identify cancer-associated TCR clones; (4) structural modeling of TCRs and TCR-peptide-major histocompatibility complex (MHC), which is used to predict the three-dimensional structures of TCRs with or without their targets; (5) TCR specificity prediction, which predicts whether a given TCR can bind to a given peptide-MHC complex; and finally (6) functional and clinical integration, addressing the breakthroughs and bottlenecks for wider clinical application of these methods. For each category, we discuss the underlying methodologies, representative tools and their key applications, details about usability and accessibility, and comments on their strengths and limitations. With this overview, we offer a critical perspective on the current state of the field, providing an overall framework and guidance for new users and developers of these technologies. We also highlight open challenges and key future directions, particularly regarding the integration of multi-omics data and next-generation artificial intelligence approaches to unlock the full potential of TCR repertoire analysis for clinical immunotherapy applications.

Indexed as

Computational BiologyImmunotherapyNeoplasmsReceptors, Antigen, T-CellAnimalsHumansImmunoinformaticsTranslational Research, BiomedicalReceptors, Antigen, T-CellImmunotherapyMajor histocompatibility complex - MHCT cellT cell Receptor - TCR

Identifiers

PMID42315254
PMCPMC13289238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.